Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medicago sativa pollen is a biologic allergenic extract derived from the pollen of the Medicago sativa plant, also known as alfalfa. It is used as a diagnostic agent to identify allergic sensitivities in patients with suspected inhalant allergies. The extract contains proteins and allergens from alfalfa pollen that, when administered through skin prick testing, provoke an IgE-mediated immune response in sensitized individuals. This localized reaction helps confirm an allergy to alfalfa pollen. It was first approved in the United States in 1965 and is manufactured by several companies as an injectable solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Medicago sativa pollen.